Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...

The Scottish Medicines Consortium announced lecanemab would not be made available on the NHS, following a similar decision ...

Nearly every disease has an inflammatory component, but blood tests can't pinpoint inflammation in specific organs or tissues ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...